Cevoglitazar

SKU: orb1700886

Description

Cevoglitazar (LBM-642) is a dual agonist of PPARα and PPARγ. It has demonstrated potent efficacy in reducing food consumption and body weight in preclinical studies using obese rodent and non-human primate models, supporting metabolic disease research.

Research Area

Metabolism Research, Molecular Biology

Key Properties

• CAS Number: 839673-52-8
• MW: 558.53
• Purity: 98.75% (May vary between batches)
• Formula: C₂₇H₂₁F₃N₂O₆S
• SMILES: S(=O)(=O)(N1C=2C(C[C@@H]1C(O)=O)=CC=CC2)C3=CC=C(OCC=4N=C(OC4C)C5=CC=C(C(F)(F)F)C=C5)C=C3
• Target: PPAR
• Solubility: DMSO:50 mg/mL (89.52 mM)

Bioactivity

• In Vivo:
  Cevoglitazar (0.5 mg/kg; 7 d) plasma levels of glucose and insulin were normalized. Cevoglitazar (50 and 500 mg/kg; obese and insulin-resistant cynomolgus monkeys; 4 weeks) lowered food intake and body weight in a dose-dependent manner. In these animals, cevoglitazar also reduced fasting plasma insulin and, at the highest dose, reduced hemoglobin A1c levels by 0.4%. Cevoglitazar (5 mg/kg) reduced BW gain and adiposity, independent of food intake. In the muscle, cevoglitazar improves the lipid profile via both PPARalpha- and PPARgamma-mediated mechanisms, and cevoglitazar reduced hepatic lipid concentration below baseline levels (p < 0.05). Metabolic profiling showed that in the liver, cevoglitazar functions largely through PPARalpha agonism resulting in increased beta-oxidation. Cevoglitazar only induced small changes to the lipid composition of visceral fat.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LBM 642, LBM642, LBM-642, Cevoglitazar, PPARγ, PPARα

Compound Identifiers

PubChem CID

10175076